Most Popular Posts Today
In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the role of selinexor in the treatment of multiple myeloma, emphasizing its value in patients with del(17p)-positive relapsed/refractory (R/R) disease. Dr Richardson also highlights some of the challenges associated with the use of selinexor, and clinical trials evaluating the safety and efficacy of this agent. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
This is the introductory video to a series of videos that will chronicle my stem cell transplant journey. This series will educate...
Most Popular This Week
In a new investigation, ProPublica reporters Lylla Younes, Ava Kofman, Al Shaw, Lisa Song, and Maya Miller used EPA data processing software to examine the spread of cancer-causing chemicals and other hazardous air pollutions in communities across the United States. At the maps intimate scale, its possible to see up close how a massive chemical
HealthTree University, provided by the HealthTree Foundation, offers a comprehensive online multiple myeloma curriculum with lessons, quizzes and course discussion. Learn for free at https://www.healthtree.org. Topics covered include: myeloma basics, testing and blood markers, stem cell transplant, financial resources, immunotherapies, myeloma genetics and much more. We've partnered with over 100 myeloma experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University.Follow HealthTree:Twitter: https://www.twitter.com/healthtreeformmFacebook: https://www.facebook.com/healthtreeformultiplemyelomaInstagram: https://www.instragram.com/healthtreeformultiplemyeloma